Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
The Therapeutic Effect of Mrna Vaccines in Glioma: A Comprehensive Review Publisher Pubmed



Afrashteh F1, 2 ; Seyedpour S3, 4 ; Rezaei N2, 3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Student Research Committee, School of Medicine, Iran University of Medical Sciences (IUMS), Tehran, Iran
  2. 2. Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran
  3. 3. Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children’s Medical Center, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Nanomedicine Research Association (NRA), Universal Scientific Education and Research Network (USERN), Tehran, Iran

Source: Expert Review of Clinical Immunology Published:2025


Abstract

Introduction: Glioma is the most common primary brain tumor, with glioblastoma being the most lethal type due to its heterogeneous and invasive nature of the cancer. Current therapies have low curative success and are limited to surgery, radiotherapy, and chemotherapy. More than 50% of patients become resistant to chemotherapy, and tumor recurrence occurs in most patients following an initial course of therapy. Therefore, developing novel, effective strategies for glioma treatment is essential. Cancer vaccines are novel therapies that demonstrate advantages over conventional methods and, therefore, may be promising options for treating glioma. Areas covered: This article provided a critical review of pre-clinical and clinical studies that explored appropriate tumor antigen candidates for developing mRNA vaccines and discussed their clinical application in glioma patients. Medline database, PubMed, and ClinicalTrials.gov were searched for glioma vaccine studies published before 2025 using related keywords. Expert opinion: mRNA vaccines are promising strategies for treating glioma because they are efficient, cost-beneficial, and have lower side effects than other types such as peptide or DNA-based vaccines. © 2025 Informa UK Limited, trading as Taylor & Francis Group.
Related Docs
View other Related Docs
1. Mrna Cancer Vaccines From Bench to Bedside: A New Era in Cancer Immunotherapy, Biomarker Research (2024)
2. Recent Advances in Glioma Cancer Treatment: Conventional and Epigenetic Realms, Vaccines (2022)
3. Tumor Immunology, Clinical Immunology (2022)
4. The Clinical Impact of Mrna Therapeutics in the Treatment of Cancers, Infections, Genetic Disorders, and Autoimmune Diseases, Heliyon (2024)
5. Delayed Effect of Dendritic Cells Vaccination on Survival in Glioblastoma: A Systematic Review and Meta‐Analysis, Current Oncology (2022)
6. Smart Biomaterials to Enhance the Efficiency of Immunotherapy in Glioblastoma: State of the Art and Future Perspectives, Advanced Drug Delivery Reviews (2021)
7. Recent Approaches to Mrna Vaccine Delivery by Lipid-Based Vectors Prepared by Continuous-Flow Microfluidic Devices, Future Medicinal Chemistry (2022)
8. Preclinical Assessment of Immunogenicity and Protectivity of Novel Ror1 Fusion Proteins in a Mouse Tumor Model, Cancers (2022)
Experts (# of related papers)
View all Related Experts
Nima Rezaei (4)
Mohammad Hossein Modarressi (2)
Other Related Docs
9. Design and Development of Modified Mrna Encoding Core Antigen of Hepatitis C Virus: A Possible Application in Vaccine Production, Iranian Biomedical Journal (2019)
10. Gene Therapy and Genetic Vaccines, Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition (2020)
11. Tumor Immunotherapies by Immune Checkpoint Inhibitors (Icis); the Pros and Cons, Cell Communication and Signaling (2022)
12. Characterization of Stability, Safety and Immunogenicity of the Mrna Lipid Nanoparticle Vaccine Iribovax® Against Covid-19 in Nonhuman Primates, Journal of Controlled Release (2023)
13. Development of Neoantigens: From Identification in Cancer Cells to Application in Cancer Vaccines, Expert Review of Vaccines (2022)
14. Development of Dendritic Cell Loaded Mage-A2 Long Peptide; a Potential Target for Tumor-Specific T Cell-Mediated Prostate Cancer Immunotherapy, Cancer Cell International (2023)
15. Immunotherapeutic Approaches for Cancer Therapy: An Updated Review, Artificial Cells# Nanomedicine and Biotechnology (2016)
16. Dna Vaccines As Promising Immuno-Therapeutics Against Cancer: A New Insight, Frontiers in Immunology (2024)
17. Repurposing the Anti-Parasitic Agent Pentamidine for Cancer Therapy; a Novel Approach With Promising Anti-Tumor Properties, Journal of Translational Medicine (2025)
18. Emerging Immunologic Approaches As Cancer Anti-Angiogenic Therapies, Clinical and Translational Oncology (2025)
19. The Role of Cell Membrane-Coated Nanoparticles As a Novel Treatment Approach in Glioblastoma, Frontiers in Molecular Biosciences (2023)
20. Immunotherapy a New Hope for Cancer Treatment: A Review, Pakistan Journal of Biological Sciences (2018)
21. Nanovaccines for Cancer Immunotherapy: Focusing on Complex Formation Between Adjuvant and Antigen, International Immunopharmacology (2023)
22. Biological Products in Medicine, Encyclopedia of Toxicology# Fourth Edition: Volume 1-9 (2023)
23. The Potential Use of Therapeutics and Prophylactic Mrna Vaccines in Human Papillomavirus (Hpv), Virology Journal (2024)
24. Gene Therapy in Glioblastoma Multiforme: Can It Be a Role Changer?, Heliyon (2024)
25. Vaccine Design and Delivery Approaches for Covid-19, International Immunopharmacology (2021)
26. Could Artificial Intelligence Revolutionize the Development of Nanovectors for Gene Therapy and Mrna Vaccines?, Nano Today (2022)